Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Shareholders OK GE Acquisition

NEW YORK, March 17 (GenomeWeb News) - Amersham shareholders today gave thumbs up to the company's acquisition by General Electric, one of the final approval hurdles facing the $9.5 billion proposed merger, which was announced in October.


Amersham shareholders, by proxy and at a court meeting and an extraordinary general meeting held today in London, approved the share-exchange acquisition, the company said.


The transaction, which is still subject to approval by the British High Court, Amersham said, is expected to be completed on April 8. The pricing of the share exchange will be calculated based on the trading period between March 23 and April 5, Amersham said.


Under the terms of the merger, William Castell, the chief executive officer of Amersham, will become a vice chairman of General Electric and Amersham will become General Electric Healthcare Technologies, the first of GE's divisions headquartered outside the US.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.